首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNA
【24h】

Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNA

机译:使用靶向心肌细胞特异性mRNA的分子信标从分化多能干细胞中纯化心肌细胞

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND - : Although methods for generating cardiomyocytes from pluripotent stem cells have been reported, current methods produce heterogeneous mixtures of cardiomyocytes and noncardiomyocyte cells. Here, we report an entirely novel system in which pluripotent stem cell-derived cardiomyocytes are purified by cardiomyocyte-specific molecular beacons (MBs). MBs are nanoscale probes that emit a fluorescence signal when hybridized to target mRNAs. METHOD AND RESULTS - : Five MBs targeting mRNAs of either cardiac troponin T or myosin heavy chain 6/7 were generated. Among 5 MBs, an MB that targeted myosin heavy chain 6/7 mRNA (MHC1-MB) identified up to 99% of HL-1 cardiomyocytes, a mouse cardiomyocyte cell line, but <3% of 4 noncardiomyocyte cell types in flow cytometry analysis, which indicates that MHC1-MB is specific for identifying cardiomyocytes. We delivered MHC1-MB into cardiomyogenically differentiated pluripotent stem cells through nucleofection. The detection rate of cardiomyocytes was similar to the percentages of cardiac troponin T- or cardiac troponin I-positive cardiomyocytes, which supports the specificity of MBs. Finally, MHC1-MB-positive cells were sorted by fluorescence-Activated cell sorter from mouse and human pluripotent stem cell differentiating cultures, and ≈97% cells expressed cardiac troponin T or cardiac troponin I as determined by flow cytometry. These MB-based sorted cells maintained their cardiomyocyte characteristics, which was verified by spontaneous beating, electrophysiological studies, and expression of cardiac proteins. When transplanted in a myocardial infarction model, MB-based purified cardiomyocytes improved cardiac function and demonstrated significant engraftment for 4 weeks without forming tumors. CONCLUSIONS - : We developed a novel cardiomyocyte selection system that allows production of highly purified cardiomyocytes. These purified cardiomyocytes and this system can be valuable for cell therapy and drug discovery.
机译:背景技术:尽管已经报道了从多能干细胞产生心肌细胞的方法,但目前的方法产生的是心肌细胞和非心肌细胞的异质混合物。在这里,我们报告了一个全新的系统,其中多能干细胞衍生的心肌细胞被心肌细胞特异性分子信标(MBs)纯化。 MB是与探针mRNA杂交时发出荧光信号的纳米级探针。方法和结果-:产生了5个靶向心肌肌钙蛋白T或肌球蛋白重链6/7 mRNA的MB。在5 MB中,靶向肌球蛋白重链6/7 mRNA(MHC1-MB)的MB最多可识别99%的HL-1心肌细胞(一种小鼠​​心肌细胞系),但在流式细胞仪分析中,只有不到3%的4种非心肌细胞类型,这表明MHC1-MB对识别心肌细胞具有特异性。我们通过核转染将MHC1-MB递送到心肌分化的多能干细胞中。心肌细胞的检出率与心肌肌钙蛋白T或心肌肌钙蛋白I阳性心肌细胞的百分比相似,这支持了MB的特异性。最后,通过荧光激活细胞分选仪从小鼠和人多能干细胞分化培养物中分选出MHC1-MB阳性细胞,流式细胞术测定约有97%的细胞表达心肌肌钙蛋白T或心肌肌钙蛋白I。这些基于MB的分选细胞保持了其心肌细胞特征,这已通过自发搏动,电生理研究和心脏蛋白表达得到证实。当以心肌梗塞模型移植时,基于MB的纯化心肌细胞可改善心脏功能,并在4周内显示出明显的植入,而没有形成肿瘤。结论-:我们开发了一种新型的心肌细胞选择系统,该系统可以生产高度纯化的心肌细胞。这些纯化的心肌细胞和该系统对于细胞治疗和药物发现非常有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号